<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136123">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832480</url>
  </required_header>
  <id_info>
    <org_study_id>4042013</org_study_id>
    <nct_id>NCT01832480</nct_id>
  </id_info>
  <brief_title>Trichomonas Vaginalis Repeat Infections Among HIV Negative Women</brief_title>
  <official_title>Trichomonas Vaginalis Repeat Infections Among HIV Negative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University Health Sciences Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to determine the influence of patient treatment, host
      factors and partner treatment on repeat Trichomonas vaginalis (TV) infections among
      HIV-negative women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase IV two-factorial (dosing and partner treatment) randomized clinical
      trial. HIV-negative women who test positive for TV at their routine gynecological exam at
      participating clinics will be referred to the nurse/study coordinator to screen for
      eligibility, provide a description of the study, and obtain written, informed consent
      (N=2883). Subjects will undergo an audio computer assisted self- interview (ACASI), and will
      self-collect a vaginal swab for Gram stain testing and be randomized into one of four arms
      based on 2 factors; dosing -- metronidazole (MTZ) 2 g single dose (CDC recommended treatment
      regimen) or MTZ 500 mg BID 7-day dose (CDC alternative treatment regimen); and partner
      treatment -- patient-delivered partner treatment (PDPT) or partner referral (PR). The four
      arms are MTZ single dose/PDPT, MTZ single dose/PR, MTZ 7d dose/PDPT, and MTZ 7d dose/PR. All
      enrolled women will be asked to return for a follow-up visit at one month after baseline
      (window 4-6 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>TV negative after treatment with either multi or single dose MTZ</measure>
    <time_frame>1 month post treatment completion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2883</enrollment>
  <condition>Vaginitis Trichomonal or Due to Trichomonas</condition>
  <condition>Partner Communication</condition>
  <arm_group>
    <arm_group_label>MTZ 2 g and PDPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose MTZ and Patient delivered partner treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTZ 2 g and Partner referral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose MTZ and Partner referral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole 250 mg BID and PDPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi dose MTZ and patient delivered partner treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTZ 250 mg BID and Partner referral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi dose MTZ and partner referral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTZ 250 mg BID</intervention_name>
    <description>MTZ 250 mg BID</description>
    <arm_group_label>Metronidazole 250 mg BID and PDPT</arm_group_label>
    <arm_group_label>MTZ 250 mg BID and Partner referral</arm_group_label>
    <other_name>Multi-dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDPT</intervention_name>
    <description>patient delivered partner treatment of MTZ</description>
    <arm_group_label>MTZ 2 g and PDPT</arm_group_label>
    <arm_group_label>Metronidazole 250 mg BID and PDPT</arm_group_label>
    <other_name>Patient delivered partner treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTZ 2 g</intervention_name>
    <description>MTZ 2 g</description>
    <arm_group_label>MTZ 2 g and PDPT</arm_group_label>
    <arm_group_label>MTZ 2 g and Partner referral</arm_group_label>
    <other_name>Single dose MTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Partner referral</intervention_name>
    <description>Partner Referral to seek treatment</description>
    <arm_group_label>MTZ 2 g and Partner referral</arm_group_label>
    <arm_group_label>MTZ 250 mg BID and Partner referral</arm_group_label>
    <other_name>Partner Referral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  English speaking

          -  &gt;= 18 years old (Crossroads and Delgado); &gt;=19 years old (JCDH)

        Exclusion Criteria:

          -  HIV-infected

          -  unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Kissinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Kissinger, PhD</last_name>
    <email>kissing@tulane.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jefferson County Dept of Health/STD Specialty Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Muzny, MD</last_name>
      <phone>205-975-3298</phone>
      <email>cmuzny@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Christins Muzny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delgado Personal Health Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Taylor, MD</last_name>
      <email>STaylo2@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Mena, MD</last_name>
      <phone>601-937-2387</phone>
      <email>lmena@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Harold Henderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, Myers L, Hagensee ME, Farley TA, Martin DH. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009 Jan;36(1):11-6.</citation>
    <PMID>19008776</PMID>
  </reference>
  <reference>
    <citation>Kissinger P, Secor WE, Leichliter JS, Clark RA, Schmidt N, Curtin E, Martin DH. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis. 2008 Apr 1;46(7):994-9.</citation>
    <PMID>18444815</PMID>
  </reference>
  <reference>
    <citation>Kissinger P, Schmidt N, Mohammed H, Leichliter JS, Gift TL, Meadors B, Sanders C, Farley TA. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006 Jul;33(7):445-50.</citation>
    <PMID>16531939</PMID>
  </reference>
  <reference>
    <citation>Kissinger P, Mena L, Levison J, Clark RA, Gatski M, Henderson H, Schmidt N, Rosenthal SL, Myers L, Martin DH. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):565-71. doi: 10.1097/QAI.0b013e3181eda955.</citation>
    <PMID>21423852</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 1, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University Health Sciences Center</investigator_affiliation>
    <investigator_full_name>Patricia Kissinger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Trichomonas vaginalis</keyword>
  <keyword>metronidazole</keyword>
  <keyword>Patient-delivered partner treatment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trichomonas Infections</mesh_term>
    <mesh_term>Trichomonas Vaginitis</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
